Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...
Verzenio, like many medications, carries the potential for side effects, with common ones including abdominal pain, nausea, vomiting, and fatigue. So it’s important to discuss any concerns with a ...
INDIANAPOLIS, June 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) has met the primary ...
Verzenio's label expanded to include the full study population investigated in the Verzenio Phase 3 monarchE trial. Approval supported by four-year data from the monarchE trial; Verzenio added to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback